There are definite advantages to the cost-benefit ratio of bloodless medicine.”—Diego Piazza, president of the Italian Medical Association of Catania, director of oncological surgery at the Garibaldi-Nesima Hospital of Catania, former president of the Italian Association of Hospital Surgeons (ACOI) “The apparent ‘harmless’ nature of blood transfusions, their perceived easy availability, their relatively low cost, the ease with which they can be prescribed, and the possibility to immediately observe their effectiveness (in terms of increased hemoglobin levels)—all these aspects have contributed to their widespread use.
Kéèyàn tọ́jú aláìsàn láìlo ẹ̀jẹ̀ máa dín ìnáwó kù gan-an, òun ló sì dáa jù.”​—⁠Diego Piazza, tó jẹ́ ààrẹ ẹgbẹ́ Italian Medical Association of Catania, òun ni olùdarí ẹ̀ka tó ń tọ́jú àìsàn jẹjẹrẹ ní Ilé Ìwòsàn Garibaldi-Nesima ní ìlú Catania, òun sì ni ààrẹ ẹgbẹ́ Italian Association of Hospital Surgeons tẹ́lẹ̀ (ACOI) “Àwọn dókítà kan rò pé kò séwu nínú kéèyàn gba ẹ̀jẹ̀ sára. Wọ́n nífẹ̀ẹ́ sí ìfàjẹ̀sínilára torí pé ó rọrùn láti gbà, kò wọ́n rárá, ó sì rọrùn láti dábàá rẹ̀ fún aláìsàn. Ohun míì tó jẹ́ kí wọ́n fẹ́ láti máa fa ẹ̀jẹ̀ síni lára ni pé ó tètè máa ń jẹ́ kí èròjà hemoglobin nínú sẹ́ẹ̀lì pupa inú ẹ̀jẹ̀ lọ sókè lára aláìsàn. Ìdí nìyẹn tí ọ̀pọ̀ dókítà fi máa ń fa ẹ̀jẹ̀ síni lára.